Current stock page

Financial Data

CNMD Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

CNMDCONMED Corporation

Healthcare / Medical - Devices

Leader

Strong Relative Position

BullishEdge 9/10
$48.01−$0.38 (−0.79%)

Latest quote

  • Momentum
    74
  • Value
    84
  • Quality
    66
  • Risk resilience
    58
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 30, 2026, compared with the same quarter a year earlier.

Revenue
$335.56M
−0.9% YoY
Net income
$19.8M
+592.4% YoY
Free cash flow
$46.73M
−3.7% YoY
Operating margin
11.1%
+5.3 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

CNMD, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue−0.9%$336M$343M$317M$373M$339M$343M$319M$346M
Gross profit+19.7%$189M$197M$183M$213M$158M$181M$168M$198M
Operating income+91.5%$37M$36M$25M$67M$19M$42M$11M$52M
Net income+592.4%$20M$23M$14M$17M$3M$21M$6M$34M
EPS (diluted)+616.6%$0.66$0.77$0.45$0.54$0.09$0.69$0.19$1.08
Gross margin+9.7 pts56.4%57.5%57.9%57.1%46.7%52.6%52.6%57.3%
Operating margin+5.3 pts11.1%10.6%8.0%17.9%5.7%12.2%3.6%15.2%
Net margin+5.1 pts5.9%6.7%4.4%4.5%0.8%6.2%1.9%9.8%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow−8.0%$49M$37M$13M$46M$54M$29M$42M$43M
Capital expenditure+48.3%−$3M−$3M−$3M−$5M−$5M−$6M−$4M−$4M
Free cash flow−3.7%$47M$34M$11M$41M$48M$23M$38M$39M
Free cash flow margin−0.4 pts13.9%9.9%3.3%11.0%14.3%6.8%11.8%11.4%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets−0.8%$2.30B$2.30B$2.31B$2.33B$2.32B$2.33B$2.30B$2.31B
Total liabilities−5.3%$1.24B$1.26B$1.30B$1.29B$1.31B$1.33B$1.32B$1.34B
Shareholders' equity+5.1%$1.06B$1.04B$1.02B$1.03B$1.01B$1.00B$978M$963M
Total debt−4.4%$816M$834M$861M$835M$854M$882M$892M$906M
Cash and equivalents+23.2%$48M$37M$35M$41M$39M$34M$35M$24M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/E ratio−2.6518.7723.0320.4728.0621.4214.4115.0014.76
P/B ratio−0.061.301.251.101.281.361.581.822.03
Return on equity+0.6 pts6.9%5.4%5.4%4.6%6.4%11.0%12.1%13.8%
Debt to equity−0.080.770.800.850.810.850.880.910.94
Free cash flow yield−1.2 pts9.6%10.3%11.0%11.4%10.9%9.3%9.2%7.9%

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio20x
P/B ratio1.37x
Revenue growth (YoY)-0.89%
EPS growth (YoY)614.29%
Gross margin57.20%
Operating margin12.11%
ROE7.07%
ROIC5.73%
Debt to equity0.77
FCF yield9.20%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$48.01
Volume
As of Nov 13, 2026
189,716
RSI (14)
As of Nov 13, 2026
56.85
MACD
As of Nov 13, 2026
1.23
MACD signal
As of Nov 13, 2026
1.02
MACD histogram
As of Nov 13, 2026
0.21
ADX (14)
As of Nov 13, 2026
23.31
SMA (50)
As of Nov 13, 2026
$47.17
SMA (200)
As of Nov 13, 2026
$41.91
ATR (14)
As of Nov 13, 2026
$2.00
Historical volatility (annualized)
As of Nov 13, 2026
62.16%
Volume (20-day average)
As of Nov 13, 2026
392,741
Risk measures
MetricValue
Resilience score58/100
Beta0.79
Annual volatility46.99%
Max drawdown-30.29%
Sharpe ratio0.48
VaR (95%, 1-day)-3.96%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

CNMD Financial Data FAQ

What is CONMED Corporation's revenue?

CONMED Corporation's revenue is one of the core financial data points for CNMD. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is CONMED Corporation's revenue growing?

Revenue growth shows whether CONMED Corporation is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is CNMD's EPS?

CNMD's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is CONMED Corporation's net income?

CONMED Corporation's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does CONMED Corporation generate?

Free cash flow shows how much cash CONMED Corporation generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does CONMED Corporation have?

Cash and debt help frame CNMD's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.